PATIENT WEBSITE

FOR us HEALTHCARE professionals only



Dolphin image for AKYNZEO

Efficacy in preventing CINV in AC-treated patients

SEE ADDITIONAL DATA

Safety profile in CINV patients

REVIEW NOW

Clinical data demonstrate the exceptional efficacy of AKYNZEO® in preventing CINV

90% of patients receiving cisplatin experienced complete response in the overall phase1

Complete response (no emesis and no use of rescue medication) for 5 days in the overall phase (across both acute and delayed CINV) in cisplatin-treated patients1

AKYNZEO complete response data for CINV in overall phase

99% of patients receiving cisplatin experienced complete response during the acute phase with AKYNZEO1

Complete response (no emesis and no use of rescue medication) in acute and delayed CINV in cisplatin-treated patients1

AKYNZEO complete response in acute and delayed CINV

AKYNZEO study design in patients receiving cisplatin-based chemotherapy1,2

Multicenter, randomized, double-blind, double-dummy, parallel-group study1,2:

  • Primary endpoint: complete response in overall phase (0-120 hours)1
  • Patients received a HEC regimen that included cisplatin (≥50 mg/m2 either alone or in combination with other chemotherapy agents)2
    • Median cisplatin dose: 75 mg/m2 for each group1
  • Patients treated with AKYNZEO primarily had a diagnosis of lung/respiratory cancer (25.9%), head and neck cancer (24.4%), or ovarian cancer (17.8%)2
  • Dosing schedule1,2:
    • AKYNZEO arm: Day 1: AKYNZEO and oral dexamethasone 12 mg. Days 2-4: Oral dexamethasone 8 mg once a day
    • Palonosetron arm: Day 1: Oral palonosetron 0.5 mg and oral dexamethasone 20 mg. Days 2-4: Oral dexamethasone 8 mg twice a day

Efficacy in preventing CINV in AC-treated patients

SEE ADDITIONAL DATA

Safety profile in CINV patients

REVIEW NOW
References: 1. AKYNZEO® (netupitant/palonosetron) capsules Full Prescribing Information. 2. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340-1346.